<DOC>
	<DOCNO>NCT02338921</DOCNO>
	<brief_summary>To assess efficacy treatment sitagliptin dapagliflozin lobeglitazone type 2 diabetes mellitus patient , inadequate glycemic control even though use two drug combination therapy glimepiride metformin .</brief_summary>
	<brief_title>Triple Combination Therapy Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy</brief_title>
	<detailed_description>Dual combination therapy metformin sulphonylurea commonly use combination regimen treat patient type 2 diabetes . But , treatment dual combination therapy often unsuccessful achieve glycaemic control patient type 2 diabetes . Recently , various oral hypoglycemic agent develop include dipeptidyl peptidase ( DPP ) -IV inhibitor , sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor new peroxisome proliferator-activated receptor ( PPARs ) agonists . But , study glucose lower effect drug Type 2 diabetes patient dual combination therapy sulfonylurea agent metformin . Hence , researcher plan investigate efficacy safety drug combination sulfonylurea agent metformin type 2 diabetic patient .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>20 ≤ Age &lt; 80 year HbA1c ≥ 7 % combination therapy glimepiride metformin 2 month . dosage glimepiride : 18mg/day dosage metformin : 5002550mg/day Type 1 diabetes , gestational diabetes , secondary form diabetes Contraindication sitagliptin dapagliflozin lobeglitazone Pregnant breast feed woman Medication affect glycemic control ( ex . steroid ) Disease affect efficacy safety drug Any major illness ( Liver disease , Renal failure , Heart disease , Cancer , etc ) Not appropriate oral antidiabetic agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>triple combination therapy</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>dapagliflozin</keyword>
	<keyword>lobeglitazone</keyword>
</DOC>